Frelii Updates Strategic Roadmap to Target Five Key High Growth Market Segments

Frelii Inc. (OTCQX: FRLI), today provided a shareholder update on the Company’s strategic roadmap detailing how it will further evolve its proprietary DNA profiling artificial intelligence (AI) to meet the growing demands of targeted market segments, including medical cannabis use analysis, telehealth and precision medicine, life and health insurance, consumer wellness and hospital systems.

Frelii continues to develop and grow its patented AI technology, leveraged base code and large data sets gathered from public and private partnerships. Frelii’s predictive capacity with its precision medicine and health and wellness AI has increased from 84% to 98.5%. And the flagship high-efficiency Genetic Sequencing and analysis using Frelii’s proprietary technology has increased to greater than 99% and 99.999% accuracy on whole genome and exome sequencing, respectively. Current competitive solutions analyze approximately 400 thousand data points, generating approximately 384 outcomes, such as diet suggestions or identification of potential health risks. The Frelii AI technology has dramatically increased the data points analyzed to over 60 million, yielding more than 60 million outcomes.

Due to this continued expansion of its AI and market segment specific UI, Frelii has been able to create negotiations with institutions and organizations in each target market segment that will allow the Company to maximize its business development, strategic growth and revenue for the foreseeable future. The Company’s unique technology is particularly attractive to these select segments because of the fundamentally different approach Frelii takes using AI to interpret DNA testing results. This will allow each roadmap market segment to have much greater insight and decision making perspective than what is currently available, creating greater competitive advantage for each partner and alliance within their own respective markets.

“Current DNA analysis solutions that only take a few hundred thousand data points into consideration run the risk of phenotypic misdiagnosis,” said Ian Jenkins, CEO of Frelii. “We are providing a sea-change with our profoundly more robust technological capabilities. We enable visualization into epigenetic expression as clusters of millions of 3D models. Through this, our AI derives meaning from the clusters with true interconnected data. As such, we are opening the doors to far more specific and accurate DNA analysis and far broader applications to a number of market segments from precision medicine to life insurance and beyond.”